Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

COCP

Live52w low +30.4%

Annual Quarterly

Core line items from COCP's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: COCRYSTAL PHARMA, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Annual 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31
Revenue	$0.00	$2.01M	$1.50M	$1.01M	$461.00K
Operating Income	Not available	$-9.59M	$-8.12M	$-5.41M	$-1.96M
Net Income	Not available	$-9.65M	$-8.15M	$-3.50M	$-1.99M
EPS (Diluted)	$-0.17	Not available	Not available	$-0.12	$-0.05
Total Assets	Not available	$54.24M	$53.22M	$40.48M	$42.84M
Total Liabilities	Not available	$1.74M	$3.04M	$3.42M	$2.41M
Cash & Equivalents	Not available	$33.01M	$31.78M	$19.32M	$21.69M
Free Cash Flow OCF − CapEx	Not available	$-10.07M	$-7.69M	$-4.61M	$-2.28M
Shares Outstanding	Not available	70.44M	68.56M	52.14M	52.14M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from COCP's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +30.4%

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: COCRYSTAL PHARMA, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Annual 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31
Revenue	$0.00	$2.01M	$1.50M	$1.01M	$461.00K
Operating Income	Not available	$-9.59M	$-8.12M	$-5.41M	$-1.96M
Net Income	Not available	$-9.65M	$-8.15M	$-3.50M	$-1.99M
EPS (Diluted)	$-0.17	Not available	Not available	$-0.12	$-0.05
Total Assets	Not available	$54.24M	$53.22M	$40.48M	$42.84M
Total Liabilities	Not available	$1.74M	$3.04M	$3.42M	$2.41M
Cash & Equivalents	Not available	$33.01M	$31.78M	$19.32M	$21.69M
Free Cash Flow OCF − CapEx	Not available	$-10.07M	$-7.69M	$-4.61M	$-2.28M
Shares Outstanding	Not available	70.44M	68.56M	52.14M	52.14M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.